EGFR and non-small cell lung carcinoma: Recently, studies have revealed comparable OS and PFS among different EGFR-TKIs, gefitinib, erlotinib, and afatinib,[23] but direct comparison between afatinib, gefitinib, and erlotinib as first-line therapies for advanced NSCLC with de novo BM is still lacking.